Glenmark Pharmaceutical’s arm discovers, Initiates IND Enable Studies of GBR 830

04 Feb 2013 Evaluate

Glenmark Pharmaceuticals S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) has discovered and initiated IND enable studies of a novel clinical development candidate, GBR 830, an anti-OX40 monoclonal antibody.

GBR 830 has been discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 830, an anti-OX40 monoclonal antibody is a potential Global First-in-class molecule

OX40 is a well known target and the development of OX40 antagonists has been very challenging. The company has achieved a significant milestone with the successful generation of an antagonistic OX40 monoclonal antibody coupled with generation of data validating the role of OX40 in autoimmune diseases.

GBR 830 shows great promise to emerge as a valuable therapeutic option to treat patients suffering from immune pathologies such as autoimmune diseases like Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD).

 

Glenmark Pharma Share Price

1592.90 -33.65 (-2.07%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.